Fall Conference Agenda

One Burtt Road
Andover MA 01810

October 21, 2011

8.30-8.50 AM  Coffee and Bagels
8.50-9.00 AM  Welcome and Introduction: Dale Morris (Pfizer, MA)
9.00-9.40 AM  Carcinogenicity Studies Today: Mike Elwell (Covance, DC)
9.40-10.20 AM Use of rasH2 Model in Carcinogenicity Assessment: Prashant Nambiar, (Pfizer, CT)
10.20-11.00 AM Influence of Diet on Carcinogenicity Study Outcomes: Kevin Keenan (Charles River Laboratories, Pathology Associates, PA)
11.00-11.20 AM Break
11.20-12.00 PM A Case for New Carcinogenicity Testing Paradigm (NEGCARC): Dan Morton (Pfizer, MA)
12.00-12.40 PM FDA Comments on NEGCARC: Todd Bourcier (FDA, MD)
12.40-1.30 PM  Lunch
1.30-2.10 PM  Carcinogenicity Assessment of Biotherapeutics: David L Hutto (Eisai, MA)
2.10-2.40 PM  Rodent Tumor Combinations in Carcinogenicity Studies: Zaher Radi (Pfizer, MA)
2.40-3.00 PM  Break
3.00-3.40 PM  Balancing False-Positive Risk and Power in Statistical Analysis of Rodent Carcinogenicity Studies: Keith Soper (Merck, PA)

3.40-4.10 PM  Nongenotoxic Mechanisms of Hemangiosarcoma Formation in Mice: Leslie Obert (Pfizer, CT)

4.10-4.40 PM  Eplerenone Case Study: Renal Tubular Neoplasms Associated with Chronic Progressive Nephropathy in Rats: Mark Vogel (Pfizer, MA)

4.40-5.00 PM  Closing Remarks: Timothy MacLachlan (Novartis, MA)